The cancer-associated IDH1 mutations have been demonstrated to produce 2-hydroxyglutarate as this IDH (IDH1 and IDH2) mutant enzyme carries a neomorphic catalytic function and converts alpha-ketoglutarate to 2-hydroxyglutarate that suppresses the histone lysine demethylases (23–25). The gene discussed is IDH1; the disease is cancer.